Supreme Court rejects Teva's attempt to prevent launch of generic Copaxone
Mylan Inc. has announced that Supreme Court Chief Justice Roberts has denied Teva's application for an injunction seeking to prevent Mylan's launch of a generic version of Copaxone pending the Supreme Court's decision on Teva's appeal. This is the second time that the Chief Justice has denied Teva's request for such an injunction. Mylan expects to have approval from the FDA for its generic by 24 May 2014.
The rejection by Chief Justice John Roberts leaves Teva open to generic competition as soon as next month. Mylan Inc., Momenta Pharmaceuticals Inc. and Novartis AG Sandoz are positioned to start selling generic Copaxone in late May, although they would risk having to pay damages if Teva ultimately wins its patent-infringement case.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.